Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Holmøy T[au]:

July 2017 ENCALS statement on edaravone. Al-Chalabi A et al. Amyotroph Lateral Scler Frontotemporal Degener. (2017)

An update on cladribine for relapsing-remitting multiple sclerosis. Holmøy T et al. Expert Opin Pharmacother. (2017)

Family planning, pregnancy and breastfeeding in multiple sclerosis. Holmøy T et al. Tidsskr Nor Laegeforen. (2016)

Search results

Items: 1 to 50 of 151

1.

A young woman with seizures, visual impairment, and paralysis.

Høglund RA, Myro AZ, Zarnovicky S, Holmøy T.

Tidsskr Nor Laegeforen. 2019 Aug 19;139(11). doi: 10.4045/tidsskr.19.0122. Print 2019 Aug 20. Norwegian, English.

2.

Adverse events with fatal outcome associated with alemtuzumab treatment in multiple sclerosis.

Holmøy T, Fevang B, Olsen DB, Spigset O, Bø L.

BMC Res Notes. 2019 Aug 12;12(1):497. doi: 10.1186/s13104-019-4507-6.

3.

High BMI is associated with low ALS risk: A population-based study.

Nakken O, Meyer HE, Stigum H, Holmøy T.

Neurology. 2019 Jul 30;93(5):e424-e432. doi: 10.1212/WNL.0000000000007861. Epub 2019 Jun 26.

PMID:
31243073
4.

Persistence of intrathecal oligoclonal B cells and IgG in multiple sclerosis.

Tomescu-Baciu A, Johansen JN, Holmøy T, Greiff V, Stensland M, de Souza GA, Vartdal F, Lossius A.

J Neuroimmunol. 2019 Aug 15;333:576966. doi: 10.1016/j.jneuroim.2019.576966. Epub 2019 May 16.

PMID:
31153015
5.

B cell depletion in the treatment of multiple sclerosis.

Myhr KM, Torkildsen Ø, Lossius A, Bø L, Holmøy T.

Expert Opin Biol Ther. 2019 Mar;19(3):261-271. doi: 10.1080/14712598.2019.1568407. Epub 2019 Jan 23. Review.

PMID:
30632834
6.

Diffuse alveolar hemorrhage during alemtuzumab infusion in a patient with multiple sclerosis: a case report.

Myro AZ, Bjerke G, Zarnovicky S, Holmøy T.

BMC Pharmacol Toxicol. 2018 Nov 19;19(1):75. doi: 10.1186/s40360-018-0267-5.

7.

G1m1 predominance of intrathecal virus-specific antibodies in multiple sclerosis.

Tomescu-Baciu A, Vartdal F, Holmøy T, Vedeler CA, Lossius A.

Ann Clin Transl Neurol. 2018 Sep 17;5(10):1303-1309. doi: 10.1002/acn3.642. eCollection 2018 Oct.

8.

The right not to know about amyotrophic lateral sclerosis

Nakken O, Holmøy T.

Tidsskr Nor Laegeforen. 2018 Oct 15;138(16). doi: 10.4045/tidsskr.18.0734. Print 2018 Oct 16. Norwegian. No abstract available.

9.

Vitamin D supplementation and neurofilament light chain in multiple sclerosis.

Holmøy T, Røsjø E, Zetterberg H, Blennow K, Lindstrøm JC, Steffensen LH, Kampman MT.

Acta Neurol Scand. 2019 Feb;139(2):172-176. doi: 10.1111/ane.13037. Epub 2018 Nov 12.

PMID:
30317548
10.

B-cell composition in the blood and cerebrospinal fluid of multiple sclerosis patients treated with dimethyl fumarate.

Høglund RA, Polak J, Vartdal F, Holmøy T, Lossius A.

Mult Scler Relat Disord. 2018 Nov;26:90-95. doi: 10.1016/j.msard.2018.08.032. Epub 2018 Sep 6.

PMID:
30243235
11.

Ethical challenges in tracheostomy-assisted ventilation in amyotrophic lateral sclerosis.

Magelssen M, Holmøy T, Horn MA, Fondenæs OA, Dybwik K, Førde R.

J Neurol. 2018 Nov;265(11):2730-2736. doi: 10.1007/s00415-018-9054-x. Epub 2018 Sep 14.

PMID:
30218178
12.

Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Benth JŠ, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2018 Oct 15;323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

PMID:
30196837
13.

Genetic testing in amyotrophic lateral sclerosis.

Nakken O, Sørum L, Holmøy T.

Tidsskr Nor Laegeforen. 2018 Sep 3;138(13). doi: 10.4045/tidsskr.18.0193. Print 2018 Sep 4. English, Norwegian.

14.

Extensive Multiple Sclerosis Reactivation after Switching from Fingolimod to Rituximab.

Holmøy T, Torkildsen Ø, Zarnovicky S.

Case Rep Neurol Med. 2018 Jul 19;2018:5190794. doi: 10.1155/2018/5190794. eCollection 2018.

15.

α-Linolenic acid is associated with MRI activity in a prospective cohort of multiple sclerosis patients.

Bjornevik K, Myhr KM, Beiske A, Bjerve KS, Holmøy T, Hovdal H, Midgard R, Riise T, Wergeland S, Torkildsen Ø.

Mult Scler. 2019 Jun;25(7):987-993. doi: 10.1177/1352458518779925. Epub 2018 Jun 4.

PMID:
29862891
16.

Sex ratio in multiple sclerosis mortality over 65 years; an age-period-cohort analysis in Norway.

Nakken O, Lindstrøm JC, Holmøy T.

J Neurol. 2018 Jun;265(6):1295-1302. doi: 10.1007/s00415-018-8832-9. Epub 2018 Mar 21.

PMID:
29564602
17.

Severe multiple sclerosis reactivation after gonadotropin treatment.

Torkildsen Ø, Holmøy T, Myhr KM.

Mult Scler Relat Disord. 2018 May;22:38-40. doi: 10.1016/j.msard.2018.02.031. Epub 2018 Mar 6.

PMID:
29525298
18.

Assessing amyotrophic lateral sclerosis prevalence in Norway from 2009 to 2015 from compulsory nationwide health registers.

Nakken O, Lindstrøm JC, Tysnes OB, Holmøy T.

Amyotroph Lateral Scler Frontotemporal Degener. 2018 May;19(3-4):303-310. doi: 10.1080/21678421.2017.1418004. Epub 2017 Dec 22.

PMID:
29271248
19.

Selective intrathecal enrichment of G1m1-positive B cells in multiple sclerosis.

Lossius A, Tomescu-Baciu A, Holmøy T, Vedeler CA, Røsjø E, Lorentzen ÅR, Casetta I, Vartdal F.

Ann Clin Transl Neurol. 2017 Sep 27;4(10):756-761. doi: 10.1002/acn3.451. eCollection 2017 Oct.

20.

In Silico Prediction Analysis of Idiotope-Driven T-B Cell Collaboration in Multiple Sclerosis.

Høglund RA, Lossius A, Johansen JN, Homan J, Benth JŠ, Robins H, Bogen B, Bremel RD, Holmøy T.

Front Immunol. 2017 Oct 2;8:1255. doi: 10.3389/fimmu.2017.01255. eCollection 2017.

21.

July 2017 ENCALS statement on edaravone.

Al-Chalabi A, Andersen PM, Chandran S, Chio A, Corcia P, Couratier P, Danielsson O, de Carvalho M, Desnuelle C, Grehl T, Grosskreutz J, Holmøy T, Ingre C, Karlsborg M, Kleveland G, Koch JC, Koritnik B, KuzmaKozakiewicz M, Laaksovirta H, Ludolph A, McDermott C, Meyer T, Mitre Ropero B, Mora Pardina J, Nygren I, Petri S, Povedano Panades M, Salachas F, Shaw P, Silani V, Staaf G, Svenstrup K, Talbot K, Tysnes OB, Van Damme P, van der Kooi A, Weber M, Weydt P, Wolf J, Hardiman O, van den Berg LH.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 Nov;18(7-8):471-474. doi: 10.1080/21678421.2017.1369125. Epub 2017 Oct 4. Review. No abstract available.

22.

An update on cladribine for relapsing-remitting multiple sclerosis.

Holmøy T, Torkildsen Ø, Myhr KM.

Expert Opin Pharmacother. 2017 Oct;18(15):1627-1635. doi: 10.1080/14656566.2017.1372747. Epub 2017 Sep 11. Review.

PMID:
28858531
23.

Listeria monocytogenes infection associated with alemtuzumab - - a case for better preventive strategies.

Holmøy T, von der Lippe H, Leegaard TM.

BMC Neurol. 2017 Apr 4;17(1):65. doi: 10.1186/s12883-017-0848-8.

24.

High dose vitamin D supplementation does not affect biochemical bone markers in multiple sclerosis - a randomized controlled trial.

Holmøy T, Lindstrøm JC, Eriksen EF, Steffensen LH, Kampman MT.

BMC Neurol. 2017 Apr 4;17(1):67. doi: 10.1186/s12883-017-0851-0.

25.

Re: Familieplanlegging, graviditet og amming ved multippel sklerose.

Holmøy T, Torkildsen Ø.

Tidsskr Nor Laegeforen. 2017 Feb 21;137(4):259. doi: 10.4045/tidsskr.17.0054. eCollection 2017 Feb. Norwegian. No abstract available.

PMID:
28225223
Free Article
26.

Sequence variations in C9orf72 downstream of the hexanucleotide repeat region and its effect on repeat-primed PCR interpretation: a large multinational screening study.

Nordin A, Akimoto C, Wuolikainen A, Alstermark H, Forsberg K, Baumann P, Pinto S, de Carvalho M, Hübers A, Nordin F, Ludolph AC, Weishaupt JH, Meyer T, Grehl T, Schweikert K, Weber M, Burkhardt C, Neuwirth C, Holmøy T, Morita M, Tysnes OB, Benatar M, Wuu J, Lange DJ, Bisgård C, Asgari N, Tarvainen I, Brännström T, Andersen PM.

Amyotroph Lateral Scler Frontotemporal Degener. 2017 May;18(3-4):256-264. doi: 10.1080/21678421.2016.1262423. Epub 2016 Dec 12.

PMID:
27936955
27.
28.

Family planning, pregnancy and breastfeeding in multiple sclerosis.

Holmøy T, Torkildsen Ø.

Tidsskr Nor Laegeforen. 2016 Nov 8;136(20):1726-1729. eCollection 2016 Nov. Review. English, Norwegian.

29.
30.

Negative interaction between smoking and EBV in the risk of multiple sclerosis: The EnvIMS study.

Bjørnevik K, Riise T, Bostrom I, Casetta I, Cortese M, Granieri E, Holmøy T, Kampman MT, Landtblom AM, Magalhaes S, Pugliatti M, Wolfson C, Myhr KM.

Mult Scler. 2017 Jun;23(7):1018-1024. doi: 10.1177/1352458516671028. Epub 2016 Sep 23.

PMID:
27663872
31.

Mortality trends of amyotrophic lateral sclerosis in Norway 1951-2014: an age-period-cohort study.

Nakken O, Lindstrøm JC, Tysnes OB, Holmøy T.

J Neurol. 2016 Dec;263(12):2378-2385. Epub 2016 Sep 1.

PMID:
27586392
32.

No association of tobacco use and disease activity in multiple sclerosis.

Kvistad S, Myhr KM, Holmøy T, Benth JŠ, Løken-Amsrud KI, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Torkildsen Ø.

Neurol Neuroimmunol Neuroinflamm. 2016 Jul 14;3(4):e260. doi: 10.1212/NXI.0000000000000260. eCollection 2016 Aug.

33.

Effect of high-dose vitamin D3 supplementation on antibody responses against Epstein-Barr virus in relapsing-remitting multiple sclerosis.

Røsjø E, Lossius A, Abdelmagid N, Lindstrøm JC, Kampman MT, Jørgensen L, Sundström P, Olsson T, Steffensen LH, Torkildsen Ø, Holmøy T.

Mult Scler. 2017 Mar;23(3):395-402. doi: 10.1177/1352458516654310. Epub 2016 Jul 11.

PMID:
27325604
34.

High-throughput sequencing of immune repertoires in multiple sclerosis.

Lossius A, Johansen JN, Vartdal F, Holmøy T.

Ann Clin Transl Neurol. 2016 Feb 25;3(4):295-306. doi: 10.1002/acn3.295. eCollection 2016 Apr. Review.

35.

Vitamin D, HLA-DRB1 and Epstein-Barr virus antibody levels in a prospective cohort of multiple sclerosis patients.

Wergeland S, Myhr KM, Løken-Amsrud KI, Beiske AG, Bjerve KS, Hovdal H, Midgard R, Kvistad SS, Holmøy T, Riise T, Torkildsen Ø.

Eur J Neurol. 2016 Jun;23(6):1064-70. doi: 10.1111/ene.12986. Epub 2016 Mar 21.

PMID:
26998820
36.

Re: Kronisk utmattelsessyndrom/myalgisk encefalopati--sykdomsmekanismer, diagnostikk og behandling.

Holmøy T.

Tidsskr Nor Laegeforen. 2016 Feb 9;136(3):204-5. doi: 10.4045/tidsskr.16.0051. eCollection 2016 Feb 9. Norwegian. No abstract available.

37.

Can vitamin D reduce inflammation in relapsing-remitting multiple sclerosis?

Holmøy T, Torkildsen Ø.

Expert Rev Neurother. 2016;16(3):233-5. doi: 10.1586/14737175.2016.1146134. Epub 2016 Feb 12. No abstract available.

PMID:
26796244
38.

The multiple sclerosis susceptibility genes TAGAP and IL2RA are regulated by vitamin D in CD4+ T cells.

Berge T, Leikfoss IS, Brorson IS, Bos SD, Page CM, Gustavsen MW, Bjølgerud A, Holmøy T, Celius EG, Damoiseaux J, Smolders J, Harbo HF, Spurkland A.

Genes Immun. 2016 Mar;17(2):118-27. doi: 10.1038/gene.2015.61. Epub 2016 Jan 14.

39.

Body mass index influence interferon-beta treatment response in multiple sclerosis.

Kvistad SS, Myhr KM, Holmøy T, Šaltytė Benth J, Wergeland S, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Bakke SJ, Michelsen AE, Aukrust P, Ueland T, Sagen JV, Torkildsen Ø.

J Neuroimmunol. 2015 Nov 15;288:92-7. doi: 10.1016/j.jneuroim.2015.09.008. Epub 2015 Sep 26.

PMID:
26531700
40.

Vitamin D supplementation and systemic inflammation in relapsing-remitting multiple sclerosis.

Røsjø E, Steffensen LH, Jørgensen L, Lindstrøm JC, Šaltytė Benth J, Michelsen AE, Aukrust P, Ueland T, Kampman MT, Torkildsen Ø, Holmøy T.

J Neurol. 2015 Dec;262(12):2713-21. doi: 10.1007/s00415-015-7902-5. Epub 2015 Oct 1.

PMID:
26429571
41.

Antiepileptic and Antidepressive Polypharmacy in Patients with Multiple Sclerosis.

Beiske GA, Holmøy T, Beiske AG, Johannessen SI, Johannessen Landmark C.

Mult Scler Int. 2015;2015:317859. doi: 10.1155/2015/317859. Epub 2015 Jun 29.

42.

Intrathecal BCR transcriptome in multiple sclerosis versus other neuroinflammation: Equally diverse and compartmentalized, but more mutated, biased and overlapping with the proteome.

Johansen JN, Vartdal F, Desmarais C, Tutturen AE, de Souza GA, Lossius A, Holmøy T.

Clin Immunol. 2015 Oct;160(2):211-25. doi: 10.1016/j.clim.2015.06.001. Epub 2015 Jun 6.

PMID:
26055752
43.

Barriers and Facilitators Related to Rehabilitation Stays in Multiple Sclerosis: A Qualitative Study.

Helland CB, Holmøy T, Gulbrandsen P.

Int J MS Care. 2015 May-Jun;17(3):122-9. doi: 10.7224/1537-2073.2014-007.

44.

WT1 and interferon-β-vitamin D association in MS: a longitudinal study.

Holmøy T, Esbensen QY, Torkildsen Ø, Wergeland S, Bjerve KS, Beiske AG, Midgard R, Šaltytė-Benth J, Hovdal H, Myhr KM.

Acta Neurol Scand. 2016 Apr;133(4):309-12. doi: 10.1111/ane.12448. Epub 2015 Jun 2.

PMID:
26037530
45.

Level of education and multiple sclerosis risk after adjustment for known risk factors: The EnvIMS study.

Bjørnevik K, Riise T, Cortese M, Holmøy T, Kampman MT, Magalhaes S, Myhr KM, Wolfson C, Pugliatti M.

Mult Scler. 2016 Jan;22(1):104-11. doi: 10.1177/1352458515579444. Epub 2015 May 26.

46.

Impact of the environment on multiple sclerosis.

Løken-Amsrud KI, Lossius A, Torkildsen Ø, Holmøy T.

Tidsskr Nor Laegeforen. 2015 May 19;135(9):856-60. doi: 10.4045/tidsskr.14.0751. eCollection 2015 May 19. Review. English, Norwegian.

47.

The EnvIMS Study: Design and Methodology of an International Case-Control Study of Environmental Risk Factors in Multiple Sclerosis.

Magalhaes S, Pugliatti M, Casetta I, Drulovic J, Granieri E, Holmøy T, Kampman MT, Landtblom AM, Lauer K, Myhr KM, Parpinel M, Pekmezovic T, Riise T, Wolfson D, Zhu B, Wolfson C.

Neuroepidemiology. 2015;44(3):173-81. doi: 10.1159/000381779. Epub 2015 May 7.

48.

Timing of use of cod liver oil, a vitamin D source, and multiple sclerosis risk: The EnvIMS study.

Cortese M, Riise T, Bjørnevik K, Holmøy T, Kampman MT, Magalhaes S, Pugliatti M, Wolfson C, Myhr KM.

Mult Scler. 2015 Dec;21(14):1856-64. doi: 10.1177/1352458515578770. Epub 2015 May 6.

49.

Vitamin D status and effect of interferon-β1a treatment on MRI activity and serum inflammation markers in relapsing-remitting multiple sclerosis.

Røsjø E, Myhr KM, Løken-Amsrud KI, Bakke SJ, Beiske AG, Bjerve KS, Hovdal H, Lilleås F, Midgard R, Pedersen T, Šaltytė Benth J, Torkildsen Ø, Wergeland S, Michelsen AE, Aukrust P, Ueland T, Holmøy T.

J Neuroimmunol. 2015 Mar 15;280:21-8. doi: 10.1016/j.jneuroim.2015.02.001. Epub 2015 Feb 11.

PMID:
25773151
50.

Unstable terminality: negotiating the meaning of chronicity and terminality in motor neurone disease.

Lerum SV, Solbraekke KN, Holmøy T, Frich JC.

Sociol Health Illn. 2015 Jan;37(1):81-96. doi: 10.1111/1467-9566.12182.

PMID:
25601066

Supplemental Content

Loading ...
Support Center